Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib Plus Pembrolizumab in Refractory Metastatic Melanoma
NCT05764395Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rigosertib in melanoma, sponsored by Vanderbilt-Ingram Cancer Center. Started May 2023; status: terminated.
02
Drugs
rigosertib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05764395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05764395.